Papilocare Vaginal Gel 21 canulas of 5 ml

Product Information

Gel reepitelizant al zonei de transformare a colului uterin pentru prevenirea si tratamentul coadjuvant al leziunilor cauzate de HPV.

Papilocare® este un gel care funcționează prin crearea unui strat pe mucoasa cervicală, formând o barieră defensivă pentru a preveni riscul integrării HPV. În acest fel, se întrerupe integrarea HPV, formarea de noi leziuni și, de asemenea, ajută la reepitelizarea leziunilor existente. De asemenea, stimulează refacerea microbiotei uterului. Pentru cine este Papilocare®? stvara zaštitni sloj koji brzo smanjuje nelagodu, stvarajući odgovarajuće uvjete za poticanje prirodnog procesa ozdravljenja.Changes in the cervical re-epithelization score (Likert scale) between baseline and the 3- and 6-month visits. Values are expressed as the mean together with the SD (between parentheses). *χ 2 test. Vaginal Health Prvi mjesec: Primjenjuje se jedan aplikator dnevno tijekom 21 uzastopnog dana, nakon čega slijedi odmor od 7 dana. A nonstatistically significant trend toward a higher HPV clearance was observed at 6 months in the treatment group (31/52 [59.6%] of the patients, with missing data for 1 patient) compared with the control group (41.9% [13/31], p = .118). Scheme B with Papilocare showed significant differences in clearance compared with the control group (75.9% vs 41.9%, p = .008), whereas no significant differences were observed with scheme A (39.1% vs 41.9%, p = .836). In the HR HPV group, a trend toward greater clearance was observed among the treated patients compared with the control group (62.5% vs 40.0%, p = .076). In this patient cohort, scheme B also resulted in significant differences in clearance with respect to the control group (81.8% vs 40.0%, p = .004), whereas scheme A did not (38.9% vs 40.0%, nonsignificant). Cervical Re-epithelization Liječenje traje 6 mjeseci, a po potrebi i dulje, prema uputi liječnika. Za postizanje željenih rezultata važno je dovršiti ukupno trajanje liječenja. Preporučuje se započeti liječenje nakon mjesečnice.

Papilocare ne smiju primijeniti osobe s poznatom preosjetljivošću na bilo koji od njegovih sastojaka. Ako nakon primjene osjetite nelagodu, prekinite primjenu i obratite se liječniku. Nisu dostupni podaci o primjeni Papilocare-a zajedno s kontracepcijskim sredstvima za A Papilocare® weboldalt a Richter Gedeon Nyrt. üzemelteti. A portál szerkesztését és karbantartását a HealthLinePR-Med Kommunikációs Ügynökség végzi a Richter Gedeon Nyrt. megbízásából.

Medicamente din aceeasi categorie

Approximately 30% of Spanish women younger than 30 years are HPV carriers. 25 The likelihood of HPV infection decreases over time, from 47% between the ages of 15 and 19 years to 12% in women older than 45 years. 26 The HPV is a fundamental factor for the development of cervical cancer. 27 The World Health Organization has recently established the elimination of cervical cancer as a priority medium-term objective. 28 This trial aimed to explore whether treatment with Papilocare provides better results than the conventional watchful waiting strategy in improving low-grade cervical lesions, which are the first step in the natural history of cervical cancer. 29 Clearance of LSILs after a conservative approach is of approximately 59% within 2 years of the diagnosis. Nevertheless, the likelihood of progression of these lesions to a high-grade squamous intraepithelial lesion within 5 years is 12.7%. 30 In addition, treatments for cervical cancer severely compromise the reproductive health of women. In a systematic review of Cochrane, Kyrgiou et al. 31 demonstrated a higher baseline risk for prematurity in women with cervical intraepithelial neoplasia, which increased with excisional and ablative treatments. Therefore, the scenario is conflicting, as choosing an excisional or ablative approach for the treatment of LSILs can result in negative reproductive outcomes, but avoiding treatment and just monitoring the disease results in its progression to high-grade lesions in 12 of 100 women. The current recommendation in Spain also includes monitoring the disease. 32,33 However, based on the results of this present study, a novel strategy involving Papilocare has become available. The results of this treatment in the repair of low-grade lesions have demonstrated to significantly exceed those obtained with the watchful waiting approach (8 in 10 women achieved a normalization in their lesions). Approximately 30% of Spanish women younger than 30 years are HPV carriers. 25 The likelihood of HPV infection decreases over time, from 47% between the ages of 15 and 19 years to 12% in women older than 45 years. 26 The HPV is a fundamental factor for the development of cervical cancer. 27 The World Health Organization has recently established the elimination of cervical cancer as a priority medium-term objective. 28 This trial aimed to explore whether treatment with Papilocare provides better results than the conventional watchful waiting strategy in improving low-grade cervical lesions, which are the first step in the natural history of cervical cancer. 29 Clearance of LSILs after a conservative approach is of approximately 59% within 2 years of the diagnosis. Nevertheless, the likelihood of progression of these lesions to a high-grade squamous intraepithelial lesion within 5 years is 12.7%. 30 In addition, treatments for cervical cancer severely compromise the reproductive health of women. In a systematic review of Cochrane, Kyrgiou et al. 31 demonstrated a higher baseline risk for prematurity in women with cervical intraepithelial neoplasia, which increased with excisional and ablative treatments. Therefore, the scenario is conflicting, as choosing an excisional or ablative approach for the treatment of LSILs can result in negative reproductive outcomes, but avoiding treatment and just monitoring the disease results in its progression to high-grade lesions in 12 of 100 women. The current recommendation in Spain also includes monitoring the disease. 32, 33 However, based on the results of this present study, a novel strategy involving Papilocare has become available. The results of this treatment in the repair of low-grade lesions have demonstrated to significantly exceed those obtained with the watchful waiting approach (8 in 10 women achieved a normalization in their lesions). Detalii despre Papilocare Gel Vaginal, 7 canule, Gedeon Richter din categoria Aparatul genito-urinar Laura, 32 años: «Después de ser diagnosticada con VPH y tener lesiones cervicales, mi médico me recomendó usar Papilocare. Después de un par de ciclos de tratamiento, las lesiones se redujeron significativamente y mi médico quedó impresionado con los resultados. Estoy muy agradecida por este producto y lo recomiendo a cualquiera que esté luchando con el VPH».